Single-Dose, Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Humanized monoclonal antibody 3S193 (90Y-hu3S193) in patients with advanced ovarian cancer

Trial Profile

Single-Dose, Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Humanized monoclonal antibody 3S193 (90Y-hu3S193) in patients with advanced ovarian cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2005

At a glance

  • Drugs Monoclonal antibody 3S193 Y-90 (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top